Halmagyi GM, Rudge P., Gresty MA, et al: Treatment of periodic alternating nystagmus. Ann Neurol1980;8:609-611.
2.
Leigh RJ, Zee DS: The Neurology of Eye Movements. Philadelphia, FADavis Co, 1983, pp 203-205.
3.
Young RSK , Bergman I., Gang DI, et al: Fetal Reye-like syndrome associated with valproic acid. Ann Neurol1980;7:389.
4.
Coulter DL, Allen RJ: Pancreatitis associated with valproic acid therapy for epilepsy. Ann Neurol1980:7;92.
5.
Marescaux C. , Water JM, Micheletti G., et al: Stuporous episodes during treatment with sodium valproate: Report of seven cases. Epilepsia1982;23:297-305.
6.
Gago MC, Novo I., Segade SR: Effects of valproic acid on the urea cycle and carnitine metabolism . Int Pediatr1990;5:54-57.
7.
Matsuda I., Ohtani Y., Ninomiya N.: Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr1986;109:131-134.
8.
Ohtani Y., Endo F., Matsuda I.: Carnitine deficiency and hyperammonemia associated with valproic acid therapy . J Pediatr1982;101: 782-785.
9.
Walheim DF: The significance of the hydrogen ion concentration and the addition of ADF in the determination of ammonia. Z Hlin Chim Klin Biochim1973; 11:421-426.
10.
SPSS-X, User's Guide. Chicago, SPSS Co Inc, 1985.
11.
Schobben F. , Van der Klein E., Gabreels FJM: Pharmacokinetics of din-propylacetate in epileptic patients. Eur J Clin Pharmacol1975 ;8: 97-105.
12.
Thom H., Carter PE, Cole GF, et al: Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol1991;33:795-802.
13.
Ratnike RN, Schapel GJ, Purdie G., et al: Hyperammonemia and hepatotoxicity during chronic valproate therapy: Enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol1986;22: 100-103.
14.
Haidukewyech D., John G., Zielinski JJ, et al: Chronic valproic acid therapy and incidence of increase in venous plasma ammonia. Ther Drug Monit1985;7:290-294.
15.
Zaccara G., Campostrini R., Paganini CM, et al: Long-term treatment with sodium valproate: Monitoring of venous ammonia concentrations and adverse effects. Ther Drug Monit1987;9:34-40.
16.
Walter JM, Marescaux C., Brandt C.: Sodium-valproate associated with phenobarbital: Effects of ammonia metabolism in humans. Epilepsia1983;24:628-633.
17.
Laub MC: Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia1986;27:55-59.
18.
Coulter DL, Allen RJ, Arbor A.: Hyperammonemia with valproic acid therapy. J Pediatr1981;99:317-319.
19.
Marescaux C. , Warter JM, Laroye M., et al: Le valproate de sodium: une droge hyperammonemiante. J Neurol Sci1983;58:195-209.
20.
Marini AN, Zaret BS, Beckner RR, et al: Hepatic and renal contributions to valproic acid-induced hyperammonemia . Neurology1988;38: 365-370.
21.
Warter JM, Marescaux C., Chabrier G., et al: Increased of valproate induced hyperammonemia in normal subjects by carbonhydrate intake. Neurology1984;34:1487-1489.
22.
Thurston JH , Hauhart RE, Carroll JE, et al: A single therapeutic dose of valproate affects liver, carbohydrate, fat, adenylate, amino acid, coenzyme-A(CoA) and carnitine metabolism in infant mice: Possible clinical significance. Life Sci1985;36:1643-1651.
23.
Thurston JH , Hauhart RE, Carroll JE, et al: Single doses of valproate reduce ketonemia in infant mice: Reversal by L-carnitine. Pediatr Res1984;18:383A.
24.
Melegh BB, Kerner J., Acsadi G., et al: L-carnitine replacement therapy in chronic valproate treatment . Neuropediatrics1990;21:40-43.
